Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting NCT07487103 Sponsor: Qilu Pharmaceutical Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting

NCT07487103
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 to 75 years (both men and women are eligible).
  • People with a body mass index (BMI) between 22 and 35, which is a measure of body weight relative to height.
  • People whose HbA1c blood sugar level (a measure of average blood sugar over the past few months) is between 7.0% and 10.5%.
  • People who have been diagnosed with type 2 diabetes for at least 90 days before the screening visit.
  • People who have been taking a stable daily dose of metformin (at least 1500 mg, or at least 1000 mg if that is the most they can tolerate) for at least 90 days before the screening visit.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a personal or family history of a condition called Multiple Endocrine Neoplasia Type 2, or a type of thyroid cancer called Medullary Thyroid Carcinoma.
  • People who have a history of pancreatitis, which is inflammation of the pancreas (either a single severe episode or a long-term condition).
  • People who have had major stomach surgery that could affect how the body absorbs the trial medicine, such as full or partial stomach removal, sleeve gastrectomy, or gastric bypass surgery.
  • People whose heart condition has been classified as New York Heart Association Class IV, which refers to the most severe level of heart failure symptoms.
  • People who are already scheduled for a procedure to restore blood flow in the heart, neck, or leg arteries, as known at the time of the screening visit.
  • People whose kidneys are not functioning well enough, based on a specific blood test result that measures kidney filtering capacity (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026

Contact this trial

Phone: +86-18266419923

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 December 2026

Primary endpoints

Change in HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov